

Saudi Food and Drug Authority approves Janin Medical as Chordate Medical's Authorized Representative in KSA

Chordate Medical announces that the Saudi Food and Drug Authority (SFDA) has approved the application for registration of Janin Medical Company ("Janin") as the company's Authorized Representative in KSA. This means, among other things, that Chordate now can fill waiting purchase orders from customers.

"The formal bureaucracy can be extensive in some markets and Saudi Arabia is no exception. We as exporters need to have an Authorized Representative registered with the competent authority in most markets. It is satisfactory that the application was approved relatively fast this time, a clear sign of effective collaboration between our General Manager for the GCC area and the new distributor. We have customer orders that have had to wait for this registration, and which are now possible to deliver near term, says Anders Weilandt, CEO of Chordate.

Chordate entered into the agreement with Janin, one of Saudi Arabia's leading medical device companies, in December 2022. The agreement means that Janin started as exclusive distributor in Saudi Arabia and Bahrain for both the migraine and rhinitis indications at new year. The company is a focused importer and distributor of advanced medical devices in neurology, pulmonary medicine, cardiology, speech therapy/audiology and urology. Janin also has the status to bid for public tenders.

More information about Janin Medical Company: https://janinmedical.com/index.html

The information was submitted, through the contact person below, for publication on February 24 at 10:00 2023 (CET).

For more information, please contact:

Anders Weilandt, CEO

 $\underline{anders.weilandt@chordate.com}$

Cell: +46 733-874277



About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The K.O.S-treatment has clinically proven efficacy according to scientific studies. The company's products are available via distributors to clinics in the Nordic countries, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

Saudi Food and Drug Authority approves Janin Medical as Chordate Medical's Authorized Representative in KSA